Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment

Clinical Advances in Hematology and Oncology

Volumn 11, Issue 3, 2013, Pages 184-189

  McCloskey, James K ^a   Broome, Catherine M ^a   Cheson, Bruce D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BENDAMUSTINE; BILIRUBIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; BRONCHOSCOPY; CASE REPORT; CHOLECYSTECTOMY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; ENDOBRONCHIAL ULTRASONOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; HOARSENESS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRRITABLE COLON; LARYNGOSCOPY; LIVER DISEASE; LYMPHADENOPATHY; MALE; MEDIASTINUM MASS; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OBSTRUCTIVE JAUNDICE; THERAPY EFFECT; VOCAL CORD PARALYSIS; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LIVER DISEASES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; TREATMENT OUTCOME;

EID: 84877996682     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med. 2002;346:235-242.
2. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol (ASCO Annual Meeting Abstracts). 2012;30: Abstract 3.
3. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximabrefractory and alkylator-refractory, indolent, and transformed non-Hodgkin's lymphoma: results from a phase II multicenter single-agent study. J Clin Oncol. 2008;26:204-210.
4. Ogura M, Ando K, Niitsu N, et al. A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol (ASCO Annual Meeting Abstracts). 2012;30: Abstract 8023.
5. Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1285-1289.
6. Merseyside and Cheshire Cancer Network. Approved haematology chemotherapy protocol CHOP (21) +/- rituximab. http:www.mccn.nhs.uk/fileuploads/ Chemotherapy_Protocols/Non/CHOP.pd. Accessed August 12, 2012.
7. Flinn IW, van, de Jagt RH, Kahl BS et al. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright Study. Paper presented at the 54th American Society of Hematology Annual Meeting and Exposition; December 8-11, 2012; Atlanta, Georgia. Abstract 902.
8. Teichert J, Sohr R, Baumann F, et al. Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Dispos. 2005;33:984-992.
9. Owen JS, Melhem M, Passarell JA, D'Andrea D, Darwish M, Kahl B. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol. 2010;66:1039-1049.
10. Schoppmeyer K, Kreth F, Wiedmann M, Mössner J, Preiss R, Caca K. A pilot study of bendamustine in advanced bile duct cancer. Anticancer Drugs. 2007;18:697-702.
11. Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol. 2007;59:759-770.
12. Napp Pharmaceuticals Limited. Levact 2.5 mg/ml powder for concentrate for solution for infusion: summary of product characteristics. http://www.medicines. org.uk/EMC/medicine/23469/SPC/Levact+2.5+mg+ml+powder+for+concentrat e+for+solution+for+infusion/. Accessed August 12, 2012.
13. Cephalon Inc. Treanda_ (bendamustine hydrochloride for injection) for intravenous infusion: US prescribing information [online]. http://www.accessdata.fda. gov/drugsatfda_docs/label/2010/022249s006lbl.pdf. Accessed August 12, 2012.
14. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009;27:2892.